Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ropsacitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 known ✓ | P29597 | 20/20 | 1.00 |
| ▸ | JAK2 | O60674 | 20/20 | 1.00 |
| ▸ | JAK1 | P23458 | 20/20 | 1.00 |
| ▸ | JAK3 | P52333 | 8/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ropsacitinib SCHEMBL19253418 | 1.00 | JAK2 (1.00) | JAK2JAK1TYK2JAK3 | |
| Ropsacitinib SCHEMBL25183572 | 1.00 | JAK2 (1.00) | JAK2JAK1TYK2JAK3 | |
| Ropsacitinib SCHEMBL19271747 | 1.00 | JAK2 (1.00) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL25510190 | 0.93 | JAK2 (0.87) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL22824688 | 0.92 | JAK2 (0.84) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL20794037 | 0.92 | JAK2 (0.84) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL22824782 | 0.92 | JAK2 (0.84) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL25510014 | 0.91 | JAK2 (0.83) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL25509824 | 0.91 | JAK2 (0.83) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL19253486 | 0.91 | JAK2 (1.00) | JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 287 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705339-A1 | COMPOSITION, METHODS AND USES | 4E Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-12569487-B2 | Treatment of hidradenitis with jak inhibitors | PFIZER INC. (US) | 2026-03-10 | — | — | US | claimed |
| EP-4701663-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-03-04 | — | — | EP | claimed |
| US-20250188088-A1 | COMPOUND AND USE THEREOF | ONQUALITY PHARMACEUTICALS CHINA LTD. (CN) | 2025-06-12 | — | — | US | claimed |
| EP-4511031-A1 | TREATMENT OF NEUTROPHILIC DERMATOSES | UNION therapeutics A/S (DK) | 2025-02-26 | — | — | EP | claimed |
| US-20250032492-A1 | TREATMENT OF HIDRADENITIS WITH JAK INHIBITORS | PFIZER INC. (US) | 2025-01-30 | — | — | US | claimed |
| EP-4484429-A1 | COMPOUND AND USE THEREOF | OnQuality Pharmaceuticals China Ltd. (CN) | 2025-01-01 | — | — | EP | claimed |
| US-20240384233-A1 | Method for Producing Cardiomyocytes by Means of Reprogramming | PLASTECH PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-11-21 | — | — | US | claimed |
| WO-2024229072-A1 | COMPOSITION, METHODS AND USES | 4E THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | WO | claimed |
| WO-2024222890-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-10-31 | — | — | WO | claimed |
| WO-2021048736-A1 | TREATMENT OF HIDRADENITIS WITH JAK INHIBITORS | PFIZER INC. (US) | 2021-03-18 | — | — | WO | claimed |
| US-20200399281-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2020-12-24 | — | — | US | claimed |
| US-10822341-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | PFIZER INC. (US) | 2020-11-03 | — | — | US | claimed |
| EP-3712153-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | Pfizer Inc (US) | 2020-09-23 | — | — | EP | claimed |
| EP-3419978-B1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | PFIZER (US) | 2020-04-15 | — | — | EP | claimed |
| US-20190071448-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2019-03-07 | — | — | US | claimed |
| EP-3419978-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | Pfizer Inc (US) | 2019-01-02 | — | — | EP | claimed |
| US-10144738-B2 | Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives | PFIZER INC. (US) | 2018-12-04 | — | — | US | claimed |
| WO-2017144995-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | PFIZER INC. (US) | 2017-08-31 | — | — | WO | claimed |
| US-20170240552-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2017-08-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569487-B2 | Treatment of hidradenitis with jak inhibitors | JAK1, JAK3, JAK2 | TYK2 42/4885JAK2 3/4885JAK1 1/4885 |
| US-10822341-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | CBR3, CNR1, CCR6 | TYK2 1835/4885JAK2 923/4885JAK1 1401/4885 |
| US-10144738-B2 | Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives | JAK1, JAK2, JAK3 | TYK2 286/4885JAK2 2/4885JAK1 1/4885 |
| US-20170240552-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | CBR3, CNR1, CCR6 | TYK2 1835/4885JAK2 923/4885JAK1 1401/4885 |
| US-20200399281-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | CBR3, CNR1, CBR1 | TYK2 1885/4885JAK2 849/4885JAK1 1320/4885 |
| US-20190071448-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | CBR3, CNR1, CCR6 | TYK2 1835/4885JAK2 923/4885JAK1 1401/4885 |
| US-20250188088-A1 | COMPOUND AND USE THEREOF | CYP17A1, CYP11B2, CYP21A2 | TYK2 2974/4885JAK2 1497/4885JAK1 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.